Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

This "Cancer Fighter in a Test Tube" Play Has Given Us 56% in Two Months

Shares of TrovaGene Inc. (Nasdaq: TROV) soared nearly 16% Wednesday after the investors shrugged off a first-quarter earnings miss and focused on the impressive progress the San Diego-based company is making with its "liquid biopsy" technology.

We first recommended TrovaGene back on March 11. With yesterday's surge, folks who acted on our original call now have a 56% profit in this development-stage biotech stock in just under two months.

While the earnings report had a happy ending, it didn't have a happy beginning. When the results were released Tuesday, investors were chagrined. On Tuesday, TrovaGene said revenue surged 14.4% to $127,000 in the fiscal first quarter.

  1. THOMAS DUNLEY | November 11, 2016

    i sold trov today with a 200 loss.. the stock bounced up and dow to maybe 40.00,then the last couple od days it tanked..put it on watch list

  2. Baquar Qureshi | March 7, 2017

    I bought Trov but I am sitting on loss shall I exit or hold let me know ASAP

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK